文献速递产科母胎医学

利用生物标志物筛查早产型子痫前期:将表型分类器整合为稳健预测模型

Preterm preeclampsia screening using biomarkers: combining phenotypic classifiers into robust prediction models.
PubMed 文献 · Am J Obstet Gynecol MFM · 2023-09-20

本研究基于伦敦国王学院医院11至13周前瞻性筛查队列的病例对照数据,对1635例对照和106例早产型子痫前期孕妇的50种代谢物及现有生物标志物建模,发现按体重指数和/或种族分层组合分类器可提高早产型子痫前期的预测性能。

要点

  • 在胎盘生长因子+平均动脉压基础上加入代谢物,所有孕妇中检出率由0.43升至0.58(提高15%,P<.001)。
  • 该模型在黑人(提高14%)和白人(提高19%)及正常体重(提高19%)和肥胖(提高20%)组均改善检出,超重组未改善。
  • 按体重指数和/或种族对孕妇分类,对实现预测改善起到关键作用。

核心结论

  • 代谢物生物标志物可与胎盘生长因子、平均动脉压和子宫动脉搏动指数等现有标志物联合,改善早孕期早产型子痫前期预测中的生物标志物部分。
  • 按体重指数和/或种族对孕妇进行分类,对实现预测改善起到关键作用,提示母体表型分析可能有助于改善子痫前期等产科综合征的预测。

研究设计与样本

  • 观察性病例对照研究,取自英国伦敦国王学院医院11至13周妊娠并发症预测的大型前瞻性筛查研究。
  • 采用液相色谱-质谱法对单胎妊娠血浆中50种既往与妊娠并发症相关的代谢物进行定量。
  • 模型开发可用数据为1635例对照和106例早产型子痫前期妊娠,生物标志物数据以中位数倍数归一化。
  • 建模分4步:预测因子z标准化、在未分层及按体重指数和/或种族分层的患者集中组合建模、分类器选择、将所选分类器聚合(装袋)为最终预测模型。
  • 预测性能以受试者工作特征曲线下面积和10%假阳性率下的检出率评估。

主要发现

  • 患者集按2/3为训练集、1/3为测试集拆分用于预测模型开发和内部验证,3个预测因子组合模型的测试集曲线下面积与训练集无显著差异。
  • 50种可用代谢物中,3个预测模型共选出26种,其中21种至少贡献于3个模型中的2个。
  • 每次新预测模型的曲线下面积和检出率均显著高于参考模型。
  • 胎盘生长因子+平均动脉压+代谢物模型在所有患者中的估计检出率为0.58(95%CI 0.49-0.70),较参考模型胎盘生长因子+平均动脉压的0.43(95%CI 0.33-0.55)提高15%(P<.001)。
  • 同一模型较参考模型显著改善黑人(提高14%)和白人(提高19%)患者以及正常体重组(18.5≤体重指数<25)和肥胖组(体重指数≥30)的检出,分别多检出19%和20%的病例,但超重组未改善。

关键数值与推荐

  • 参考模型(胎盘生长因子+平均动脉压)在所有患者中的检出率为0.43(95%CI 0.33-0.55)。
  • 胎盘生长因子+平均动脉压+代谢物模型在所有患者中的检出率为0.58(95%CI 0.49-0.70),较参考模型提高15%(P<.001)。
  • 黑人患者检出率提高14%,白人患者提高19%。
  • 正常体重组(18.5≤体重指数<25)多检出19%的病例,肥胖组(体重指数≥30)多检出20%的病例。

临床怎么用

  • 原文结论认为代谢物生物标志物可与现有标志物联合以改善早孕期早产型子痫前期预测,母体表型分析可能有助于改善产科综合征预测。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Preeclampsia screening is a critical component of antenatal care worldwide. Currently, the most developed screening test for preeclampsia at 11 to 13 weeks' gestation integrates maternal demographic characteristics and medical history with 3 biomarkers-serum placental growth factor, mean arterial pressure, and uterine artery pulsatility index-to identify approximately 75% of women who develop preterm preeclampsia with delivery before 37 weeks of gestation. It is generally accepted that further improvements to preeclampsia screening require the use of additional biomarkers. We recently reported that the levels of specific metabolites and metabolite ratios are associated with preterm preeclampsia. Notably, for several of these markers, preterm preeclampsia prediction varied according to maternal body mass index class. These findings motivated us to study whether patient classification allowed for combining metabolites with the current biomarkers more effectively to improve prediction of preterm preeclampsia. OBJECTIVE: This study aimed to investigate whether metabolite biomarkers can improve biomarker-based preterm preeclampsia prediction in 3 screening resource scenarios according to the availability of: (1) placental growth factor, (2) placental growth factor+mean arterial pressure, and (3) placental growth factor+mean arterial pressure+uterine artery pulsatility index. STUDY DESIGN: This was an observational case-control study, drawn from a large prospective screening study at 11 to 13 weeks' gestation on the prediction of pregnancy complications, conducted at King's College Hospital, London, United Kingdom. Maternal blood samples were also collected for subsequent research studies. We used liquid chromatography-mass spectrometry to quantify levels of 50 metabolites previously associated with pregnancy complications in plasma samples from singleton pregnancies. Biomarker data, normalized using multiples of medians, on 1635 control and 106 preterm preeclampsia pregnancies were available for model development. Modeling was performed using a methodology that generated a prediction model for preterm preeclampsia in 4 consecutive steps: (1) z-normalization of predictors, (2) combinatorial modeling of so-called (weak) classifiers in the unstratified patient set and in discrete patient strata based on body mass index and/or race, (3) selection of classifiers, and (4) aggregation of the selected classifiers (ie, bagging) into the final prediction model. The prediction performance of models was evaluated using the area under the receiver operating characteristic curve, and detection rate at 10% false-positive rate. RESULTS: First, the predictor development methodology itself was evaluated. The patient set was split into a training set (2/3) and a test set (1/3) for predictor model development and internal validation. A prediction model was developed for each of the 3 different predictor panels, that is, placental growth factor+metabolites, placental growth factor+mean arterial pressure+metabolites, and placental growth factor+mean arterial pressure+uterine artery pulsatility index+metabolites. For all 3 models, the area under the receiver operating characteristic curve in the test set did not differ significantly from that of the training set. Next, a prediction model was developed using the complete data set for the 3 predictor panels. Among the 50 metabolites available for modeling, 26 were selected across the 3 prediction models; 21 contributed to at least 2 out of the 3 prediction models developed. Each time, area under the receiver operating characteristic curve and detection rate were significantly higher with the new prediction model than with the reference model. Markedly, the estimated detection rate with the placental growth factor+mean arterial pressure+metabolites prediction model in all patients was 0.58 (95% confidence interval, 0.49-0.70), a 15% increase (P<.001) over the detection rate of 0.43 (95% confidence interval, 0.33-0.55) estimated for the reference placental growth factor+mean arterial pressure. The same prediction model significantly improved detection in Black (14%) and White (19%) patients, and in the normal-weight group (18.5≤body mass index<25) and the obese group (body mass index≥30), with respectively 19% and 20% more cases detected, but not in the overweight group, when compared with the reference model. Similar improvement patterns in detection rates were found in the other 2 scenarios, but with smaller improvement amplitudes. CONCLUSION: Metabolite biomarkers can be combined with the established biomarkers of placental growth factor, mean arterial pressure, and uterine artery pulsatility index to improve the biomarker component of early-pregnancy preterm preeclampsia prediction tests. Classification of the pregnant women according to the maternal characteristics of body mass index and/or race proved instrumental in achieving improved prediction. This suggests that maternal phenotyping can have a role in improving the prediction of obstetrical syndromes such as preeclampsia.

来源:Am J Obstet Gynecol MFM,查看原文。版权归原作者所有。

引用

  1. Thomas G, Syngelaki A, Hamed K, et al. Preterm preeclampsia screening using biomarkers: combining phenotypic classifiers into robust prediction models. Am J Obstet Gynecol MFM. 2023. PMID: 37752025. doi:10.1016/j.ajogmf.2023.101110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。